CTORCitius Oncology Inc.
CTOR
Citius Oncology Inc.1,351
Mkt Cap
$81.21MVolume
66,615.0052W High
$6.1952W Low
$0.4912PE Ratio
-3.10CTOR Fundamentals
Price
$0.9297Prev Close
$0.9569Open
$0.968450D MA
$0.8306Beta
-2.21Avg. Volume
141,223.96EPS (Annual)
-$0.338P/B
1.39$148.61
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization PR Newswire CRANFORD, N.J., May 5, 2026 Avenue Capital Group to...
PR Newswire·17h ago
Citius Oncology Ships First International Order of LYMPHIR to Europe
Citius Oncology Ships First International Order of LYMPHIR to Europe Citius Oncology Ships First International Order of LYMPHIR to Europe PR Newswire CRANFORD, N.J., April 29, 2026 Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional...
PR Newswire·7d ago
Citius Oncology (NASDAQ:CTOR) Trading 9% Higher - What's Next?
Citius Oncology (NASDAQ:CTOR) Trading Up 9% - Time to Buy...
MarketBeat·18d ago
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...
PR Newswire·1mo ago
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire·1mo ago
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened
Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.8% - Time to Sell...
MarketBeat·1mo ago
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·2mo ago
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·2mo ago
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling...
MarketBeat·2mo ago
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates
Citius Oncology (NASDAQ:CTOR - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of...
MarketBeat·3mo ago
<
1
2
...
>